These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 10813207)

  • 1. Progressive systemic sclerosis and the lung.
    Veeraraghavan S; Sharma OP
    Curr Opin Pulm Med; 1998 Sep; 4(5):305-9. PubMed ID: 10813207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scleroderma lung disease.
    Solomon JJ; Olson AL; Fischer A; Bull T; Brown KK; Raghu G
    Eur Respir Rev; 2013 Mar; 22(127):6-19. PubMed ID: 23457159
    [No Abstract]   [Full Text] [Related]  

  • 3. Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy.
    Jain S; Shahane A; Derk CT
    Inflamm Allergy Drug Targets; 2012 Aug; 11(4):266-77. PubMed ID: 22506881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging lung disease in systemic sclerosis.
    Strollo D; Goldin J
    Curr Rheumatol Rep; 2010 Apr; 12(2):156-61. PubMed ID: 20425026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians.
    Mangat P; Conron M; Gabbay E; Proudman SM;
    Intern Med J; 2010 Jul; 40(7):494-502. PubMed ID: 19460060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Systemic sclerosis].
    Schinke S; Riemekasten G
    Internist (Berl); 2019 Dec; 60(12):1251-1269. PubMed ID: 31754753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
    Colaci M; Giuggioli D; Sebastiani M; Manfredi A; Lumetti F; Luppi F; Cerri S; Ferri C
    Reumatismo; 2015 Dec; 67(4):149-55. PubMed ID: 27215180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapeutic strategies in the management of systemic sclerosis.
    Allanore Y; Avouac J; Wipff J; Kahan A
    Expert Opin Pharmacother; 2007 Apr; 8(5):607-15. PubMed ID: 17376016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lung in systemic sclerosis.
    Steen VD
    J Clin Rheumatol; 2005 Feb; 11(1):40-6. PubMed ID: 16357695
    [No Abstract]   [Full Text] [Related]  

  • 10. Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction?
    Morelli S; Ferri C
    J Rheumatol; 1996 Apr; 23(4):789-91. PubMed ID: 8730152
    [No Abstract]   [Full Text] [Related]  

  • 11. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
    Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
    Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs and therapeutics for systemic sclerosis.
    Lee JJ; Pope JE
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary complications: one of the most challenging complications of systemic sclerosis.
    Wells AU; Steen V; Valentini G
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii40-4. PubMed ID: 19487223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial lung disease in systemic sclerosis: current and future treatment.
    Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
    Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic sclerosis sine scleroderma presenting as pulmonary intersticial fibrosis.
    Vañó Sanchis D; Arranz Garcia G; Yglesias PJ
    Clin Rheumatol; 2006 May; 25(3):382-3. PubMed ID: 16211337
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of vasodilators in patients with progressive systemic sclerosis. Interstitial lung disease and pulmonary hypertension.
    Ohar J; Polatty C; Robichaud A; Fowler A; Vetrovec G; Glauser F
    Chest; 1985 Oct; 88(4 Suppl):263S-265S. PubMed ID: 4042734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors relating to impaired stroke volume during the 6-minute walk test in patients with systemic sclerosis.
    Someya F; Mugii N; Oohata S
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):152-156. PubMed ID: 27463117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis.
    Broad K; Pope JE
    Med Sci Monit; 2010 Sep; 16(9):RA187-90. PubMed ID: 20802426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment and management of scleroderma lung disease.
    Bolster MB; Silver RM
    Curr Opin Rheumatol; 1999 Nov; 11(6):508-13. PubMed ID: 10551676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis.
    Zhang XJ; Bonner A; Hudson M; ; Baron M; Pope J
    J Rheumatol; 2013 Jun; 40(6):850-8. PubMed ID: 23547215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.